Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia

被引：0
|
作者：
Fathi, Amir Tahmasb
Arevalo, Mabel
Gutierrez, Sonia
Molero, Antonieta
Sacilotto, Natalia
Limon, Ana E.
Faller, Douglas V.
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[2] Oryzon Genom, Barcelona, Spain
[3] 69 Parkton Rd, Boston, MA USA
[4] Oryzon Genom, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7075
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary
    Bradley, Terrence
    Tiu, Ramon, V
    Naqvi, Kiran
    Dail, Monique
    Brackman, Deanna
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +
  • [12] Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel L.
    Qualtieri, Julianne N.
    Watt, Christopher D.
    Morrissette, Jennifer J. D.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD ADVANCES, 2019, 3 (10) : 1581 - 1585
  • [13] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
    Hosono, Naoko
    Yokoyama, Hisayuki
    Aotsuka, Nobuyuki
    Ando, Kiyoshi
    Iida, Hiroatsu
    Ishikawa, Takayuki
    Usuki, Kensuke
    Onozawa, Masahiro
    Kizaki, Masahiro
    Kubo, Kohmei
    Kuroda, Junya
    Kobayashi, Yukio
    Shimizu, Takayuki
    Chiba, Shigeru
    Nara, Miho
    Hata, Tomoko
    Hidaka, Michihiro
    Fujiwara, Shin-Ichiro
    Maeda, Yoshinobu
    Morita, Yasuyoshi
    Kusano, Mikiko
    Lu, Qiaoyang
    Miyawaki, Shuichi
    Berrak, Erhan
    Hasabou, Nahla
    Naoe, Tomoki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2131 - 2141
  • [14] FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
    Pulte, E. Dianne
    Norsworthy, Kelly J.
    Wang, Yaping
    Xu, Qing
    Qosa, Hisham
    Gudi, Ramadevi
    Przepiorka, Donna
    Fu, Wentao
    Okusanya, Olanrewaju O.
    Goldberg, Kirsten B.
    De Claro, R. Angelo
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3515 - 3521
  • [15] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
    Naoko Hosono
    Hisayuki Yokoyama
    Nobuyuki Aotsuka
    Kiyoshi Ando
    Hiroatsu Iida
    Takayuki Ishikawa
    Kensuke Usuki
    Masahiro Onozawa
    Masahiro Kizaki
    Kohmei Kubo
    Junya Kuroda
    Yukio Kobayashi
    Takayuki Shimizu
    Shigeru Chiba
    Miho Nara
    Tomoko Hata
    Michihiro Hidaka
    Shin-Ichiro Fujiwara
    Yoshinobu Maeda
    Yasuyoshi Morita
    Mikiko Kusano
    Qiaoyang Lu
    Shuichi Miyawaki
    Erhan Berrak
    Nahla Hasabou
    Tomoki Naoe
    International Journal of Clinical Oncology, 2021, 26 : 2131 - 2141
  • [16] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
    Briski, Robert
    Short, Nicholas J.
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Valero, Yesid Alvarado
    Vaughan, Kenneth
    Pierce, Sherry
    Montalbano, Kathryn
    Mullin, Jillian
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2023, 142
  • [17] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
    Ong, Faustine
    Short, Nicholas
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Alvarado, Yesid
    Vaughan, Kenneth
    Pierce, Sherry A.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2022, 140 : 9029 - 9031
  • [18] Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis
    Shai Shimony
    Jonathan Canaani
    Eitan Kugler
    Boaz Nachmias
    Ron Ram
    Israel Henig
    Avraham Frisch
    Chezi Ganzel
    Vladimir Vainstein
    Yakir Moshe
    Shlomzion Aumann
    Moshe Yeshurun
    Yishai Ofran
    Pia Raanani
    Ofir wolach
    Annals of Hematology, 2022, 101 : 2011 - 2011
  • [19] Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia
    Connie Kang
    Hannah A. Blair
    Targeted Oncology, 2020, 15 : 681 - 689
  • [20] Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia
    Chen, Nianci
    Zhou, Yile
    Tong, Hongyan
    Wei, Juying
    Lou, YinJun
    Zhou, De
    Fan, Cuihua
    Huang, Li
    Mao, Liping
    Li, Chenying
    Wang, Huafeng
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345